51 completed, 14 recruiting, 14 unknown, 5 terminated. 38 Phase 2, 19 Phase 3, 15 Phase 1, 14 Phase 4, 1 Not applicable.
Follow belimumab: new trials by email Literature Review of belimumab trials Research Report on belimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA) - Lupus Nephritis | Phase 4 | Recruiting | Aurinia Pharmaceuticals Inc. | 150 | 2026-04-22 | 2026-08-03 |
| Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized Belimumab Prefilled Syringe [Benlysta] - Kidney Transplant Rejection | Phase 2 | Recruiting | Leiden University Medical Center | 25 | 2026-04-01 | 2026-09-22 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus GNC-038, Belimumab - Systemic Lupus Erythematosus | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 84 | 2025-06-04 | 2026-07-10 |
| A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) Belimumab - Connective Tissue Diseases | Phase 3 | Recruiting | GlaxoSmithKline | 514 | 2024-12-12 | 2026-09-09 |
| Belimumab in Autoimmune Hepatitis Belimumab Auto-Injector [Benlysta] - Autoimmune Hepatitis | Phase 2 | Recruiting | University Health Network, Toronto | 48 | 2024-12-11 | 2026-10-22 |
| A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease Belimumab, Placebo - Lung Diseases, Interstitial | Phase 3 | Recruiting | GlaxoSmithKline | 440 | 2024-09-11 | 2026-09-08 |
| A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants GSK4527363, Placebo matching GSK4527363, Belimumab - Systemic Lupus Erythematosus | Phase 1 | Recruiting | GlaxoSmithKline | 142 | 2024-09-02 | 2026-06-22 |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) Belimumab (GSK1550188) - Systemic Lupus Erythematosus | Phase 4 | Active not recruiting | GlaxoSmithKline | 303 | 2024-06-06 | 2026-09-01 |
| A Model About the Response of Belimumab in SLE Belimumab - Systemic Lupus Erythematosus | Phase 4 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 72 | 2024-06-01 | 2023-09-21 |
| Belimumab After Rituximab in Resistant Primary Juvenile SS Rituximab, Belimumab - Sjogren's Syndrome, Pediatric ALL | Phase 4 | Recruiting | Peking Union Medical College Hospital | 15 | 2024-03-09 | 2024-05-16 |
| A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Belimumab, Placebo - Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | Phase 2 / Phase 3 | Recruiting | GlaxoSmithKline | 300 | 2023-09-13 | 2026-09-08 |
| Belimumab in SLE Synovial Inflammation and Lymph Nodes Belimumab - Systemic Lupus Erythematosus | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 15 | 2023-09-01 | 2024-03-25 | |
| A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus Belimumab, Standard of care - Systemic Lupus Erythematosus | Phase 1 | Completed | GlaxoSmithKline | 16 | 2023-07-07 | 2025-11-14 |
| Belimumab In Prevention of LN Belimumab - Whether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis | Unknown | RenJi Hospital | 48 | 2023-06-01 | 2022-10-19 | |
| Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents - Lupus Nephritis, Remission | Phase 3 | Unknown | Nanjing University School of Medicine | 15 | 2023-04-01 | 2023-05-18 |
| The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study Belimumab, Telitacicept - Lupus Nephritis, Belimumab | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 60 | 2022-10-20 | 2022-10-20 | |
| The BeLimumab Antiphospholipid Syndrome Trial (BLAST) Belimumab - Antiphospholipid Syndrome | Phase 2 / Phase 3 | Unknown | University of Turin, Italy | 15 | 2022-06-01 | 2023-01-13 |
| Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus Belimumab, Interleukin-2 - Systemic Lupus Erythematosus | Phase 3 | Unknown | Peking University People's Hospital | 10 | 2022-04-01 | 2022-03-25 |
Showing 20 of 92. Sign in to see all of them.
Lupus Erythematosus, Systemic (47) · Autoimmune Diseases (16) · Lupus Nephritis (7) · Arthritis, Rheumatoid (5) · Lung Diseases, Interstitial (4) · Sjogren's Syndrome (4) · Connective Tissue Diseases (3) · Glomerulonephritis, Membranous (3) · Granulomatosis with Polyangiitis (3) · Scleroderma, Diffuse (3) · Scleroderma, Systemic (3) · Vasculitis (3) · Dermatomyositis (2) · Glomerulonephritis (2) · Immune System Diseases (2)
GlaxoSmithKline (28) · Human Genome Sciences Inc., a GSK Company (10) · Human Genome Sciences Inc. (8) · Assistance Publique - Hôpitaux de Paris (3) · Leiden University Medical Center (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Peking Union Medical College Hospital (3) · Hospital for Special Surgery, New York (2) · Nanjing University School of Medicine (2) · Northwell Health (2) · RenJi Hospital (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Aurinia Pharmaceuticals Inc. (1) · Biomedical Research Foundation, Academy of Athens (1) · Cancer Trials Australia (1)
United States (46) · China (20) · France (18) · Spain (18) · Canada (16) · Germany (16) · Italy (16) · United Kingdom (16) · Argentina (15) · Mexico (13) · Japan (12) · Netherlands (12) · Brazil (11) · South Korea (11) · Belgium (10)
Robert Spiera, MD (2) · A J Rabelink, MD, PhD (1) · Ali Naji, MD, Ph D (1) · Andrew Spencer (1) · Anselm Mak (1) · Betty Diamond, M.D. (1) · Cynthia Aranow, M.D. (1) · Cynthia Aranow, MD (1) · David Foley, MD (1) · David Ritchie (1) · David Wofsy, M.D. (1) · Dimitrios T Boumpas, MD (1) · E. Steve Woodle, MD (1)
PMID 34628605, PMID 34741731, PMID 34531304, PMID 38775637, PMID 33687069, PMID 39115551, PMID 39208825, PMID 38216728, PMID 38724182, PMID 23213069, PMID 31302695, PMID 33568389, PMID 37228028, PMID 22275291, PMID 22337213, PMID 22674457, PMID 23524886, PMID 23681782, PMID 23754628, PMID 24187095, PMID 25396065, PMID 29409143, PMID 32918459, PMID 33830377, PMID 35302581, PMID 38258369, PMID 40256631, PMID 10398604, PMID 18786258, PMID 19714604, PMID 19714615, PMID 20039404, PMID 21296403, PMID 22127708, PMID 22707609, PMID 23547209, PMID 25740829, PMID 26336930, PMID 26639390, PMID 28118533, PMID 29073351, PMID 29336179, PMID 29636274, PMID 29661905, PMID 29671280, PMID 29807477, PMID 29910042, PMID 30055091, PMID 30320964, PMID 30666823
2023 (4), 2015 (1), 2016 (1)